SEGMENT INFORMATION (Tables)

6 Months Ended

12 Months Ended

Mar. 31, 2026

Sep. 30, 2025

SEGMENT INFORMATION

Schedule of information regarding operations by segment

Information regarding operations by segment for the three-months ended March 31, 2026 is as follows:



		Therapeutic DNA			DNA Tagging and
		Production			Security Products			Digital Asset Treasury			Consolidated
Revenues:
Product revenues		$	638,423		$	369,480		$	—		$	1,007,903
Service revenues			—			16,208			—			16,208
Less intersegment revenues			—			—			—			—
Total revenues		$	638,423		$	385,688		$	—		$	1,024,111

Gross profit			474,858			351,928			—		$	826,786

Segment operating expenses
Selling, general and administrative		$	106,894		$	71,577		$	734,934		$	913,405
Realized gain on derivative written call options			(21,573)									(21,573)
Loss from fair value measurement of digital assets			—			—			2,086,347			2,086,347
Loss from fair value measurement of investments			—			—			2,548,799			2,548,799
Research and development			364,667			19,227			—			383,894
Total segment operating expenses		$	449,988		$	90,804		$	5,370,080		$	5,910,872
Income (loss) from segment operations (a)		$	24,870		$	261,124		$	(5,370,080)		$	(5,084,086)

Information regarding operations by segment for the three-months ended March 31, 2025 is as follows:



		Therapeutic DNA			DNA Tagging and				MDx Testing
		Production			Security Products			Services and Kits			Consolidated
Revenues:
Product revenues		$	419,412		$	129,226		$	—		$	548,638
Service revenues			47,797			166,387			—			214,184
Clinical laboratory service revenues			—			—			221,272			221,272
Less intersegment revenues			—			—			(720)			(720)
Total revenues		$	467,209		$	295,613		$	220,552		$	983,374

Gross profit			290,735			132,395			(52,283)			370,847
Segment operating expenses
Selling, general and administrative		$	1,053,968		$	329,904		$	298,839		$	1,682,711
Research and development			652,473			60,127			73,129			785,729
Total segment operating expenses		$	1,706,441		$	390,031		$	371,968		$	2,468,440
Loss from segment operations (a)		$	(1,415,706)		$	(257,636)		$	(424,251)		$	(2,097,593)

Information regarding operations by segment for the six-months ended March 31, 2026 is as follows:



		Therapeutic DNA			DNA Tagging and
		Production			Security Products			Digital Asset Treasury			Consolidated
Revenues:
Product revenues		$	1,088,971		$	474,025		$	—		$	1,562,996
Service revenues			1,263			25,246			—			26,509
Clinical laboratory service revenues			—			—			—			—
Less intersegment revenues			—			—			—			—
Total revenues		$	1,090,234		$	499,271		$	—		$	1,589,505

Gross profit			783,468			358,675			—			1,142,143
Segment operating expenses
Selling, general and administrative		$	624,386		$	118,557		$	10,591,028		$	11,333,971
Realized gain on derivative written call options			—			—			(21,573)			(21,573)
Loss from fair value measurement of digital assets			—			—			3,818,904			3,818,904
Loss from fair value measurement of investments			—			—			6,032,808			6,032,808
Research and development			786,641			44,070			—			830,711
Total segment operating expenses		$	1,411,027		$	162,627		$	20,421,167			21,994,821
(Loss) income from segment operations (a)		$	(627,559)		$	196,048		$	(20,421,167)		$	(20,852,678)

Information regarding operations by segment for the six months ended March 31, 2025 is as follows:



		Therapeutic DNA			DNA Tagging and			MDx Testing
		Production			Security Products			Services and Kits			Consolidated
Revenues:
Product revenues		$	507,408		$	537,077		$	—		$	1,044,485
Service revenues			107,242			481,386			—			588,628
Clinical laboratory service revenues			—			—			548,438			548,438
Less intersegment revenues									(1,560)			(1,560)
Total revenues		$	614,650		$	1,018,463		$	546,878		$	2,179,991

Gross profit			403,233			649,758			1,963			1,054,954

Segment operating expenses
Selling, general and administrative		$	1,856,769		$	1,038,060		$	551,924		$	3,446,753
Research and development			1,424,798			197,776			136,766			1,759,340
Total segment operating expenses		$	3,281,567		$	1,235,836		$	688,690		$	5,206,093
Loss from segment operations (a)		$	(2,878,334)		$	(586,078)		$	(686,727)		$	(4,151,139)

Information regarding operations by segment for the fiscal year ended September 30, 2025 is as follows:



		Therapeutic DNA			DNA Tagging and
		Production			Security Products			Consolidated
Revenues:
Product revenues		$	828,806		$	595,341		$	1,424,147
Service revenues			159,312			553,476			712,788
Total revenues		$	988,118		$	1,148,817		$	2,136,935

Gross profit		$	336,666		$	502,241		$	838,907
Segment operating expenses
Selling, general and administrative		$	4,203,069		$	1,273,113		$	5,476,182
Research and development			5,436,239			140,267			5,576,506
Total segment operating expenses		$	9,639,308		$	1,413,380		$	11,052,688
(Loss) income from segment operations (a)		$	(9,302,642)		$	(911,139)		$	(10,213,781)

Information regarding operations by segment for the fiscal year ended September 30, 2024 is as follows:



		Therapeutic DNA			MDx Testing			DNA Tagging and
		Production			Services and Kits			Security Products			Consolidated
Revenues:
Product revenues		$	560,000		$	—		$	514,813		$	1,074,813
Service revenues			335,354			—			703,323			1,038,677
Clinical laboratory service revenues			—			1,330,849			—			1,330,849
Less intersegment revenues			—			(12,920)			—			(12,920)
Total revenues		$	895,354		$	1,317,929		$	1,218,136		$	3,431,419

Gross profit		$	678,167		$	(49,831)		$	388,543		$	1,016,879
Segment operating expenses
Selling, general and administrative		$	3,065,288		$	1,127,462		$	2,245,935		$	6,438,685
Research and development			2,402,151			311,927			694,585			3,408,663
Total segment operating expenses		$	5,467,439		$	1,439,389		$	2,940,520		$	9,847,350
(Loss) income from segment operations (a)		$	(4,789,272)		$	(1,489,220)		$	(2,551,977)		$	(8,830,469)

Schedule of reconciliation of segment loss from operations to corporate net loss

Reconciliation of segment loss from operations to consolidated loss before provision for income taxes is as follows for the three months ended:



		March 31,
		2026			2025
Loss from operations of reportable segments (a)		$	(5,084,086)		$	(2,097,593)
General corporate expenses (b)			(1,666,497)			(1,364,202)
Interest income			3,761			60,340
Unrealized gain on change in fair value of warrants classified as a liability			—			68,430
Other income (expense), net			81,663			(3,095)
Consolidated loss before provision for income taxes		$	(6,665,159)		$	(3,336,120)

(a)	Segment operating loss consists of net sales, less cost of sales, specifically identifiable research and development, and selling, general and administrative expenses.

(b)	General corporate expenses consist of Selling, general and administrative expenses that are not specifically identifiable to a segment.

Reconciliation of segment loss from operations to consolidated loss before provision for income taxes is as follows for the six months ended:



		March 31,
		2026			2025
Loss from operations of reportable segments		$	(20,852,678)		$	(4,151,139)
General corporate expenses (b)			(4,606,186)			(2,274,657)
Interest income			12,904			131,780
Unrealized gain on change in fair value of warrants classified as a liability			370			312,430
Other income (expense), net			174,249		$	(23,247)
Consolidated net loss		$	(25,271,341)		$	(6,004,833)

(a)	Segment operating loss consists of net sales, less cost of sales, specifically identifiable research and development, and selling, general and administrative expenses.

(b)	General corporate expenses consist of Selling, general and administrative expenses that are not specifically identifiable to a segment.



		September 30,
		2025			2024
Loss from operations of reportable segments		$	(10,213,781)		$	(8,830,469)
General corporate expenses (b)			(5,834,814)			(5,194,296)
Interest income			192,915			176,301
Unrealized gain on change in fair value of warrants classified as a liability			319,630			9,430,000
Unrealized loss on change in fair value of warrants classified as a liability - warrant modification			—			(394,000)
Transaction costs allocated to warrant liabilities			—			(633,198)
Loss on issuance of warrants			—			(1,633,767)
Income tax benefit			684,115			—
Net loss from discontinued operations			(392,731)			—
Other income (expense), net			(106,580)		$	(8,877)
Consolidated net loss		$	(15,349,246)		$	(7,088,306)

(a)

Segment operating loss consists of net sales less cost of sales, specifically identifiable research and development, and selling, general and administrative expenses.

(b)

General corporate expenses consists of Selling, general and administrative expenses that are not specifically identifiable to a segment.